SCHEMBL3669362

SCHEMBL3669362

[O]C(F)(C(=O)O)c1ccccc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 2/20 0.50
PTPN1 P18031 1/20 0.48
ALDH1A1 P00352 3/20 0.48
TSHR P16473 2/20 0.48
CYP2D6 P10635 1/20 0.47
CES1 P23141 2/20 0.44
MAPT P10636 3/20 0.41
KMT2A Q03164 2/20 0.41
CA1 P00915 1/20 0.41
CA2 P00918 1/20 0.41
CA5A P35218 1/20 0.41
CA9 Q16790 1/20 0.41
KCNN4 O15554 3/20 0.41
PGK1 P00558 1/20 0.40
PGK2 P07205 1/20 0.40
MEN1 O00255 1/20 0.40
HTT P42858 1/20 0.40
RAB9A P51151 1/20 0.40
CYP2C9 P11712 1/20 0.40
CYP2C19 P33261 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL354556 0.77 CYP1A2 (0.52) CYP1A2PTPN1ALDH1A1TSHRCYP2D6
SCHEMBL522914 0.77 CYP1A2 (0.52) CYP1A2PTPN1ALDH1A1TSHRCYP2D6
SCHEMBL887042 0.75 CYP1A2 (0.50) CYP1A2PTPN1ALDH1A1TSHRCYP2D6
SCHEMBL3669363 0.75 CYP1A2 (0.50) CYP1A2PTPN1ALDH1A1TSHRCYP2D6
Bromide SCHEMBL27743797 0.75 CYP1A2 (0.50) CYP1A2PTPN1ALDH1A1TSHRCYP2D6
SCHEMBL5012102 0.75 CYP1A2 (0.50) CYP1A2PTPN1ALDH1A1TSHRCYP2D6
SCHEMBL3629687 0.75 CYP1A2 (0.50) CYP1A2PTPN1ALDH1A1TSHRCYP2D6
Water SCHEMBL9562304 0.75 CYP1A2 (0.50) CYP1A2PTPN1ALDH1A1TSHRCYP2D6
SCHEMBL30274469 0.75 CYP1A2 (0.50) CYP1A2PTPN1ALDH1A1TSHRCYP2D6
SCHEMBL1826935 0.75 CYP1A2 (0.50) CYP1A2PTPN1ALDH1A1TSHRCYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9487494-B2 Cyclic hydrocarbon compounds for the treatment of diseases LEO PHARMA A/S (DK) 2016-11-08 US claimed
CN-101970394-B Novel cyclic hydrocarbon compounds for the treatment of diseases LEO PHARMA AS 2015-05-27 CN claimed
US-20100317582-A1 NOVEL CYCLIC HYDROCARBON COMPOUNDS FOR THE TREATMENT OF DISEASES LEO PHARMA A/S (DK) 2010-12-16 US claimed
EP-2234961-A2 NOVEL CYCLIC HYDROCARBON COMPOUNDS FOR THE TREATMENT OF DISEASES LEO PHARMA A/S (DK) 2010-10-06 EP claimed
WO-2009065406-A2 NOVEL CYCLIC HYDROCARBON COMPOUNDS FOR THE TREATMENT OF DISEASES LEO PHARMA A/S (DK) 2009-05-28 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100317582-A1 NOVEL CYCLIC HYDROCARBON COMPOUNDS FOR THE TREATMENT OF DISEASES ARNT, AHR, CYP27A1 CYP1A2 303/4885PTPN1 3361/4885ALDH1A1 1743/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.